ID   H1975/OR [China Guangzhou]
AC   CVCL_B0JS
DR   cancercelllines; CVCL_B0JS
DR   CCRID; 4201PAT-CCTCC01545
DR   Wikidata; Q108820356
RX   Patent=CN111793604A;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2019300.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1511 ! NCI-H1975
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 05-10-23; Version: 4
//
RX   Patent=CN111793604A;
RA   Zhang L., Pan H., Yuan Z., Zhan J.-H., Huang Y.;
RT   "Human non-small cell lung cancer cell line H1975/OR resistant to
RT   oxitinib and application thereof.";
RL   Patent number CN111793604A, 20-Oct-2020.
//